Workflow
Aligos Therapeutics Announces $105 Million Private Placement Financing
ALGSAligos Therapeutics(ALGS) GlobeNewswire·2025-02-12 12:00

Core Viewpoint - Aligos Therapeutics, Inc. has announced a private placement expected to generate approximately 105millioningrossproceedstofundthePhase2clinicalstudyofALG−000184andextenditscashrunwayintothesecondhalfof2026[1][3].Group1:PrivatePlacementDetails−Theprivateplacementisledbyalifesciencesdedicatedinvestmentfirm,withparticipationfromnewandexistinginstitutionalinvestors[2].−Aligosplanstousethenetproceedsfromtheprivateplacement,alongwithexistingcashandinvestments,toadvanceALG−000184intoaPhase2clinicalstudyforchronichepatitisBvirusinfection(CHB)andforgeneralcorporatepurposes[2][3].−Theprivateplacementinvolvesthesaleof2,103,307sharesofcommonstock,includingvotingandnon−votingshares,aswellaspre−fundedwarrantsandaccompanyingwarrantsatacombinedpriceof105 million in gross proceeds to fund the Phase 2 clinical study of ALG-000184 and extend its cash runway into the second half of 2026 [1][3]. Group 1: Private Placement Details - The private placement is led by a life sciences dedicated investment firm, with participation from new and existing institutional investors [2]. - Aligos plans to use the net proceeds from the private placement, along with existing cash and investments, to advance ALG-000184 into a Phase 2 clinical study for chronic hepatitis B virus infection (CHB) and for general corporate purposes [2][3]. - The private placement involves the sale of 2,103,307 shares of common stock, including voting and non-voting shares, as well as pre-funded warrants and accompanying warrants at a combined price of 26.0825 per share [4]. Group 2: Financial Advisors and Closing Conditions - Jefferies and Piper Sandler are acting as placement agents for the private placement, while H.C. Wainwright & Co. serves as the financial advisor [5]. - The private placement is expected to close on February 13, 2025, subject to customary closing conditions [4]. Group 3: Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases, with a mission to improve patient outcomes [8]. - The company utilizes a science-driven approach and deep R&D expertise to advance its pipeline for diseases with high unmet medical needs, including chronic hepatitis B virus infection (CHB) and metabolic dysfunction-associated steatohepatitis (MASH) [8].